Published 1 month ago • loading... • Updated 29 days ago

Asthma drug showed positive results in trials for people with nasal polyps

An asthma drug has shown positive results in trials for treating people with nasal polyps.
Participants reported significant improvements in symptoms and quality of life during the trials.
The study's findings suggest potential for broader use of the drug beyond asthma treatment.
Health experts are optimistic about the drug's potential for wider use in treatment.

Insights by Ground AI

Does this summary seem wrong?

27 Articles

All

Left

Center

Right

MedPage Today

Center

Twice-Yearly Biologic Effective Against Nasal Polyps

(MedPage Today) -- SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by a mean of 0.7 more than...

1 month ago·New York, United States

Read Full Article

Evening Standard

+4 Reposted by 4 other sources

Lean Right

Asthma drug showed positive results in trials for people with nasal polyps

Tezepelumab was first approved for treating asthma in 2021.

1 month ago·London, United Kingdom

Read Full Article

PRWeb

Center

Tezepelumab Significantly Reduces Nasal Polyp Severity and the Need for Surgery

/PRNewswire-PRWeb/ -- Fifty-two weeks of Tezepelumab significantly reduces nasal polyps in adults with chronic rhinosinusitis according to new research being...

1 month ago

Read Full Article

Helena Independent Record

+17 Reposted by 17 other sources

Center

POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery

1 month ago·Helena, United States

Read Full Article

European Pharmaceutical Manufacturer

Phase III WAYPOINT trial shows positive results

Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen's Tezspire (tezepelumab) significantly reduced nasal polyp severity.

29 days ago

Read Full Article

Pharma Excipients

PLGA-Based Strategies for Intranasal and Pulmonary Applications - Pharma Excipients

Abstract Poly(D,L-lactide-co-glycolide) (PLGA) has emerged as a cornerstone in the development of advanced drug delivery systems, particularly for intranasal and pulmonary routes. Its biodegradability, biocompatibility, and adaptability make it an ideal platform for addressing challenges associated with conventional therapies. By enabling sustained and controlled drug release, PLGA formulations reduce dosing frequency, improve patient compliance…

1 month ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year